X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ONO-4059 (tirabrutinib) is a highly selective irreversible Bruton's tyrosine kinase inhibitor. It is being evaluated for the treatment of patients with relapsed or refractory primary central nervous system lymphoma.
Lead Product(s): Tirabrutinib Hydrochloride
Therapeutic Area: Oncology Product Name: ONO-4059
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
Under the collaboration, Ono Pharmaceutical will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of CNS disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Sibylla Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2024
Details:
Through collaboration, InveniAI will identify novel therapeutic targets in multiple diseases specified by Ono by leveraging InveniAI's AlphaMeld and ChatAlphaMeld, its AI drug discovery platforms including cutting-edge technologies.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: InveniAI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 20, 2024
Details:
Through collaboration, Ono has obtained rights for NM49 from Numab for global development and commercialization, which is a multi-specific antibody designed to activate tumor-associated macrophage phagocytosis for the treatment of cancers.
Lead Product(s): NM49
Therapeutic Area: Oncology Product Name: NM49
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Numab Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 14, 2024
Details:
Under the collaboration, Shattuck will lead discovery research of certain prespecified compounds directed toward a pair of targets selected by Ono from Shattuck’s pipeline of bifunctional fusion proteins in autoimmune and inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Shattuck Labs
Deal Size: $227.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 13, 2024
Details:
Under the agreement, EVQLV will generate and provide therapeutic antibody designs against multiple therapeutic targets selected by Ono, using EVQLV's proprietary Artificial Intelligence (AI)- powered Antibody Design Engine.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: EVQLV
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 21, 2023
Details:
The collaboration aims to identify and validate novel targets within one of Ono’s priority domains of cancer biology. Turbine will apply its end-to-end, interpretable cell simulation technology, the Simulated Cell™ platform, to the in silico discovery of novel targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Turbine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 24, 2023
Details:
Under the terms of the agreement, Adimab will discover novel therapeutic antibodies against multiple targets selected by Ono and generate bispecific antibody product candidates. Ono will evaluate and develop such candidates at the pre-clinical and clinical stages.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Adimab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
Under the terms of the agreement, Twist will utilize the Twist Biopharma Solutions Library of Libraries to conduct research activities to discover novel antibodies against targets identified by Ono for the treatment of autoimmune diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Twist Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 31, 2023
Details:
The collaboration aims to examine the efficacy and safety of Opdivo, an immune checkpoint inhibitor, for resectable rectal cancer with dMMR. NCCHE will recruit patients and conduct the trial, Ono will provide nivolumab, and Personalis will perform MRD and biomarker testing.
Lead Product(s): Nivolumab
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Personalis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
